Chaz L Stucken1, John R de Almeida1, Andrew G Sikora1,2, Charles C L Tong1, Eric M Genden1,2. 1. Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York. 2. The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Abstract
BACKGROUND: The purpose of this study was to evaluate oncologic outcomes of head and neck squamous cell carcinoma (HNSCC) treated with transoral robotic surgery (TORS) based on human papillomavirus (HPV) and smoking risk factors. METHODS: Fifty-five patients with HNSCC treated with TORS, neck dissection, +/- adjuvant chemotherapy, and/or radiation therapy were retrospectively analyzed based on HPV and smoking status. RESULTS: Smokers and nonsmokers had locoregional control rates of 96.3% and 94.4% (p = .66) and progression-free survival rates 83% and 94.1% (p = .09), respectively. HPV-negative and HPV-positive patients had locoregional control rates of 87.1% and 100% (p = .03) and progression-free survival rates of 74.2% and 95.2% (p = .01), respectively. Locoregional control rates for HPV-negative smokers, HPV-negative nonsmokers, HPV-positive smokers, and HPV-positive nonsmokers were 90.9%, 80.0%, 100%, and 100% (p = .18), whereas progression-free survival rates were 72.2%, 80.0%, 92.3%, and 100% (p = .04), respectively. CONCLUSION: HPV status may be more important than smoking status in determining the risk of disease recurrence and death in patients treated with TORS.
BACKGROUND: The purpose of this study was to evaluate oncologic outcomes of head and neck squamous cell carcinoma (HNSCC) treated with transoral robotic surgery (TORS) based on human papillomavirus (HPV) and smoking risk factors. METHODS: Fifty-five patients with HNSCC treated with TORS, neck dissection, +/- adjuvant chemotherapy, and/or radiation therapy were retrospectively analyzed based on HPV and smoking status. RESULTS: Smokers and nonsmokers had locoregional control rates of 96.3% and 94.4% (p = .66) and progression-free survival rates 83% and 94.1% (p = .09), respectively. HPV-negative and HPV-positive patients had locoregional control rates of 87.1% and 100% (p = .03) and progression-free survival rates of 74.2% and 95.2% (p = .01), respectively. Locoregional control rates for HPV-negative smokers, HPV-negative nonsmokers, HPV-positive smokers, and HPV-positive nonsmokers were 90.9%, 80.0%, 100%, and 100% (p = .18), whereas progression-free survival rates were 72.2%, 80.0%, 92.3%, and 100% (p = .04), respectively. CONCLUSION:HPV status may be more important than smoking status in determining the risk of disease recurrence and death in patients treated with TORS.
Authors: Moonef Alotaibi; Valeria Valova; Toni HÄnsel; Carmen Stromberger; Grzegorz Kofla; Heidi Olze; Iris Piwonski; Andreas Albers; Sebastian Ochsenreither; Annekatrin Coordes Journal: In Vivo Date: 2021 Mar-Apr Impact factor: 2.155
Authors: Arun Sharma; Sapna Patel; Fred M Baik; Grant Mathison; Brendan H G Pierce; Samir S Khariwala; Bevan Yueh; Stephen M Schwartz; Eduardo Méndez Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-07-01 Impact factor: 6.223
Authors: Christian Grønhøj; Jakob Schmidt Jensen; Steffen Wagner; Christian Dehlendorff; Jeppe Friborg; Elo Andersen; Claus Wittekindt; Nora Würdemann; Shachi Jenny Sharma; Stefan Gattenlöhner; Jens Peter Klussmann; Christian von Buchwald Journal: Oncotarget Date: 2019-07-23